1. Home
  2. MOVE vs DSGN Comparison

MOVE vs DSGN Comparison

Compare MOVE & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MOVE

Movano Inc.

HOLD

Current Price

$20.00

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

HOLD

Current Price

$10.91

Market Cap

819.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MOVE
DSGN
Founded
2018
2017
Country
United States
United States
Employees
32
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
819.6M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
MOVE
DSGN
Price
$20.00
$10.91
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$15.25
AVG Volume (30 Days)
54.9K
957.8K
Earning Date
04-08-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$433,000.00
N/A
Revenue This Year
$1,460.71
N/A
Revenue Next Year
$96.77
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.51
$3.33
52 Week High
$34.87
$17.25

Technical Indicators

Market Signals
Indicator
MOVE
DSGN
Relative Strength Index (RSI) 65.86 38.12
Support Level $6.27 $9.25
Resistance Level $34.87 $13.54
Average True Range (ATR) 2.38 1.39
MACD 0.69 -0.54
Stochastic Oscillator 87.44 12.95

Price Performance

Historical Comparison
MOVE
DSGN

About MOVE Movano Inc.

Corvex Inc is an AI cloud computing company that provides computing infrastructure for artificial intelligence workloads, including GPU-accelerated computing, confidential computing, and inference services. Its offerings are used by government and enterprise customers, including those with regulated workloads, to support the deployment and operation of AI models and data processing systems. The company generates revenue from the sale of Wellness Rings, portable chargers and charging cables, ring sizers, and mobile applications.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

Share on Social Networks: